Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
Aug 2025 – Affilogic’s CEO Presenting latest data generated on our ODC program : Olivier Kitten is presenting at next Immuno-Oncology Summit 2025 latest in-vivo data on our ODC program, showing anti-tumor effect in xenografted mice.
Apr 2025 – Affilogic’s Partner Bracco Imaging published Nanofitins data in Nature Scientific Report : Bracco Imaging has published new data using HER-2 targeting Nanofitins used as diagnostic tool for the management of HER-2 positive tumors.
Around the world
BIO EUROPE 2025
Come and met us at next BIO Europe in Vienna – Austria
Nov 3-5, 2025
NLS Days 2025
Come and met us at next NLS Days convention in Gothenburg – Sweden
Oct 13-14, 2025
BIO Japan 2025
Come and met us at next Bio Japan convention – Yokohama
Oct 8-10, 2025
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More